Health Technology · Pharmaceuticals: Major · NSE: NATCOPHARM · data 2026-10-09
NATCO Pharma Limited
Health check: Strong (6.8/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹789.4
Market cap
₹15,615 cr
P/E
12.5
P/B
—
ROE
16.9%
ROCE
15.6%
Debt / equity
0.08
Dividend yield
0.56%
1-year return
-1.8%
52-week high
₹1,217.06
52-week low
₹785.76
Operating margin
24.6%
Growth
| Revenue (last 12 months) | ₹3,485 cr |
| Net profit (last 12 months) | ₹1,144 cr |
| Sales growth, 3 years (yearly) | 14.5% |
| Profit growth, 3 years (yearly) | 25.6% |
Similar companies
Cohance Lifesciences Ltd (COHANCE) · Alivus Life Sciences Ltd (ALIVUS) · Eris Lifesciences Ltd (ERIS) · Alembic Pharmaceuticals Limited (APLLTD) · Jubilant Pharmova Limited (JUBLPHARMA)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open NATCOPHARM in NSE Scanner →